Introduction {#sec1}
============

Partial nephrectomy is the preferred definitive treatment for early stage kidney cancer, with tumor ablative techniques or active surveillance reserved for patients not undergoing surgery.[@bib1] With an increase in the number of incidentally diagnosed kidney cancers and in an increasingly elderly population who may not tolerate invasive procedures,[@bib2]^,^[@bib3] stereotactic body radiation therapy (SBRT) has emerged as a potential noninvasive alternative for patients not amenable to surgery, with early reports suggesting excellent rates of local control and limited toxicity.[@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9] This study uses a large national cancer registry to assess patterns of care and survival outcomes in patients with stage I kidney cancer treated with SBRT.

Methods and Materials {#sec2}
=====================

The national cancer database was queried from 2004 to 2014 for patients who received a diagnosis of T1N0M0 kidney cancer (7 cm or less with no nodal or distant metastases). Both clinical and pathologic staging was used to determine patient inclusion. Histologic subtypes were limited to clear cell carcinoma, papillary carcinoma, renal cell not otherwise specified (NOS), and carcinoma NOS. Exclusion criteria is listed in [Figure 1](#fig1){ref-type="fig"}. Treatments were categorized as surgery (including partial and total nephrectomy), tumor ablation (including cryoablation and thermal ablation), SBRT, or observation. SBRT was defined as radiation therapy in 5 fractions or less to a total biological effective dose (BED~10~) of 72 or more assuming a tumor α/βvalue of 10. Although there is limited research into the radiobiology of kidney SBRT, studies from non-small cell lung cancer suggest a BED~10~ of approximately 70 corresponds to the lower limit of what may be considered an acceptable tumor control probability.[@bib10], [@bib11], [@bib12] Because a BED~10~ of 100 has been shown to be an important cut point for outcomes in multiple other disease sites,[@bib13]^,^[@bib14] patients receiving SBRT were dichotomized by those treated to a BED~10~ of \<100 or ≥100. This project was reviewed by our institutional review board and found to be exempted.Figure 1Consort diagram displaying. *Abbreviations*: NCDB = National Cancer Database; SBRT = stereotactic body radiation.

A propensity score was generated by multinomial logistic regression, and a Cox proportional hazard model was fit to determine association between treatment group and overall survival (OS) with propensity score adjustments for patient, demographic, and treatment characteristics, including age at diagnosis, race, sex, year of diagnosis, Charlson-Deyo comorbidity score, tumor size, laterality, histology, grade, insurance plan, rurality, median income, education, academic hospital, and distance traveled for treatment. The proportional hazard assumption was visually checked. To reduce lead time bias, patients were excluded if they died or were lost to follow-up before 2.67 months from diagnosis, corresponding to the time in which 90% of subjects had started definitive treatment. Approximately 3.5% of all patients (1.9% of surgery patients, 1.3% of tumor ablation patients, no SBRT patients, and 16.8% of observation patients) were excluded from analysis by this follow-up time constraint.

Results {#sec3}
=======

A total of 200,839 patients were included, of whom 165,298 received surgery (median follow-up 57 months), 17,196 underwent tumor ablation (median follow-up 50 months), 104 underwent SBRT (median follow-up 37 months), and 18,241 were observed (median follow-up 19 months; [Table 1](#tbl1){ref-type="table"}). The most common fractionation schemes for patients receiving SBRT were 40 Gy in 5 fractionation for the BED~10~ \<100 cohort (42 patients) and 48 Gy in 3 fractionation for the BED~10~ ≥100 cohort (62 patients; [Table 2](#tbl2){ref-type="table"}).Table 1Patient and tumor characteristicsTreatment*P* valueSurgeryTumor ablationSBRTObservation165,298(%)17,196(%)104(%)18,241(%)Age (y)\<.001 Median61697574 18-4933,31220.2%11656.8%11.0%11226.2% 50-6467,87041.1%486028.3%2423.1%390221.4% \>6464,11638.8%11,17165.0%7976.0%13,21772.5%Race\<.001 White122,02473.8%13,23076.9%7572.1%12,97271.1% Black18,67111.3%176510.3%1514.4%274915.1% Hispanic20,05512.1%182810.6%109.6%206911.3% Other45482.8%3732.2%43.8%4512.5%Sex\<.001 Female65,64439.7%641137.3%3735.6%765542.0% Male99,65460.3%10,78562.7%6764.4%10,58658.0%Year of diagnosis\<.001 200411,5977.0%4362.5%00.0%10345.7% 200512,4007.5%7354.3%00.0%12476.8% 200613,4888.2%11616.8%11.0%13197.2% 200714,3948.7%14168.2%54.8%14698.1% 200814,7538.9%176210.2%1110.6%15548.5% 200915,6009.4%190511.1%98.7%16308.9% 201015,1909.2%191711.1%1817.3%17169.4% 201116,2029.8%186410.8%1413.5%17869.8% 201216,99110.3%192811.2%1211.5%193910.6% 201317,18310.4%196411.4%2120.2%233012.8% 201417,50010.6%210812.3%1312.5%221712.2%Charlson-Deyo comorbidity score\<.001 0115,16569.7%11,55167.2%8379.8%12,17866.8% 137,41022.6%402923.4%1817.3%368520.2% 293875.7%11826.9%21.9%15558.5% 333362.0%4342.5%11.0%8234.5%Tumor stage\<.001 T1a110,01466.6%15,18888.3%6360.6%11,83764.9% T1b55,28433.4%200811.7%4139.4%640435.1%Tumor size (mm)\<.001 Median34.926.535.832.7 0-2557,24534.6%939754.6%2927.9%829445.5% 26-5081,52449.3%752743.8%6562.5%780742.8% 51-7026,52916.0%2721.6%109.6%2,14011.7%Laterality\<.001 Left79,98748.4%840748.9%4644.2%877148.1% Right85,08051.5%877551.0%5855.8%928550.9% Unknown2310.1%140.1%00.0%1851.0%Histology\<.001 Clear cell carcinoma92,15755.8%677939.4%3735.6%269314.8% Papillary carcinoma26,45716.0%246514.3%1312.5%10886.0% Renal cell carcinoma NOS46,38228.1%754543.9%4745.2%12,79270.1% Carcinoma NOS3020.2%4072.4%76.7%16689.1%Tumor grade\<.001 123,58014.3%268515.6%1110.6%9545.2% 284,04050.8%433025.2%2322.1%15458.5% 330,16118.2%6123.6%00.0%3602.0% 426231.6%350.2%00.0%500.3% Unknown24,89415.1%953455.4%7067.3%15,33284.1%Academic treatment facility\<.001 Yes65,41039.6%736242.8%4947.1%659336.1% No90,19754.6%956055.6%5451.9%11,34662.2% Unknown96915.9%2741.6%11.0%3021.7%[^1]Table 2Patient and tumor characteristics by radiation doseSBRT dose*P* valueBED \<100BED≥10042(%)62(%)Age (y).47 Median7573Charlson-Deyo comorbidity score.83 03378.6%5080.7% 1819.1%1016.1% 212.4%11.6% 300.0%11.6%Tumor stage.32 T1a2354.8%4064.5% T1b1945.2%2235.5%Tumor size (mm).06 Median39.233.5Laterality.57 Left2047.6%2641.9% Right2252.4%3658.1%Histology.16 Clear cell carcinoma2047.6%1727.4% Papillary carcinoma37.1%1016.1% Renal cell carcinoma NOS1740.5%3048.4% Carcinoma NOS24.8%58.1%Most common fractionation (fx) schemesN/A 40 Gy in 5 fx1331.0% 39 Gy in 3 fx921.4% 36 Gy in 3 fx921.4% 48 Gy in 3 fx2946.8% 45 Gy in 3 fx914.5% 50 Gy in 5 fx812.9%[^2]

At a median follow-up of 51 months, 40,489 patients (20.2%) had died with 5-year OS estimate shown in [Table 3](#tbl3){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}. On multivariable analysis with propensity score adjustment, patients undergoing surgery, tumor ablation, and SBRT were associated with a decreased risk of death compared with patients undergoing observation, with a hazard ratio (HR) of 0.25 (95% confidence interval \[CI\] 0.24-0.26, *P* \< .001), 0.36 (0.35-0.38, *P* \< .001), and 0.56 (0.39-0.79, *P* \< .001), respectively. Compared with observation, HR for risk of death for SBRT patients treated to a BED~10~ \<100 and a BED~10~ ≥100 was 0.90 (0.58-1.4, *P* = .64) and 0.34 (0.19-0.60, *P* \< .001), respectively ([Table 4](#tbl4){ref-type="table"}). A sensitivity analysis using Cox regression with propensity score adjustment stratified into quintiles provided similar results ([Table 5](#tbl5){ref-type="table"}).Table 3Unadjusted 5-year overall survival estimates by treatment groupPatients\
NEvents\
N5-year estimated OS(95% CI)*P* valueAll200,83940,4890.82(0.81, 0.82)Surgery165,29826,7680.86(0.86, 0.86)\<.001Tumor ablation17,19641800.77(0.76, 0.77)SBRT, BED \<10042200.42(0.25, 0.59)SBRT, BED ≥10062120.73(0.56, 0.84)Observation18,24195090.43(0.42, 0.43)[^3]Figure 2Kaplan-Meier survival curves of overall survival by treatment groups with SBRT cohorts combined (a and b) or separated by BED~10~ (c and d). *Abbreviations*: Abl = tumor ablation; Obs = observation; SBRT = stereotactic body radiation therapy; SRG = surgery.Table 4Cox proportional hazards regression for overall survival with propensity score adjustments[∗](#tbl4fnlowast){ref-type="table-fn"}HR(95% CI)*P* valueTreatment Observation1 Surgery0.25(0.24, 0.26)\<.001 Tumor ablation0.36(0.35, 0.38)\<.001 SBRT0.56(0.39, 0.79)\<.001 BED \<1000.9(0.58, 1.4).64 BED ≥1000.34(0.19, 0.6)\<.001Age (y) 18-491 50-641.75(1.66, 1.84)\<.001 \>642.85(2.71, 2.99)\<.001Race White1 Black0.99(0.96, 1.02).5 Hispanic0.88(0.85, 0.91)\<.001 Other0.8(0.74, 0.86)\<.001Sex Female1 Male1.16(1.13, 1.18)\<.001Year of diagnosis 2004-20091 2010-20120.89(0.87, 0.91)\<.001 2013-20140.88(0.85, 0.92)\<.001Charlson- Comorbidity Score 01 11.38(1.35, 1.41)\<.001 21.97(1.91, 2.04)\<.001 32.56(2.45, 2.68)\<.001Tumor size 0-25 mm1 26-50 mm1.21(1.19, 1.24)\<.001 51-70 mm1.56(1.52, 1.61)\<.001Laterality Left1 Right0.98(0.96, 1.00).09Histology Clear cell carcinoma1 Papillary carcinoma1.01(0.98, 1.04).67 Renal cell carcinoma NOS1.13(1.11, 1.16)\<.001 Carcinoma NOS1.33(1.25, 1.42)\<.001Grade 11 21.05(1.01, 1.08).007 3, 41.271.23-1.33\<.001[^4][^5]Table 5Cox proportional hazards regression for overall survival by propensity score stratification in quintiles[∗](#tbl5fnlowast){ref-type="table-fn"}HR(95% CI)*P* valueTreatment Observation1 Surgery0.20(0.19, 0.20)\<.001 Tumor ablation0.32(0.31, 0.33)\<.001 SBRT0.52(0.37, 0.74)\<.001 BED \<1000.85(0.55, 1.32).64 BED ≥1000.32(0.18, 0.56)\<.001[^6][^7]

Discussion {#sec4}
==========

In this analysis, we show that SBRT for primary kidney cancer is an uncommon treatment in the United States despite an increasing number of diagnosed patients, emerging evidence for the safety and efficacy of the treatment, and recent technical improvements in radiation delivery.[@bib2], [@bib3], [@bib4], [@bib5], [@bib6] We demonstrate that this is a recently adopted treatment, with no reported cases of primary kidney SBRT in 2004 or 2005 and only one case in 2006. Moreover, we show that patients treated with SBRT, and in particular, those with a BED~10~ ≥100, demonstrated an improved OS at 5 years compared with those who were observed, even after adjusting for patient and tumor characteristics. This outcome may in part reflect patient selection based on clinical factors not available or measured in covariates. For example, the median size of tumors in the higher BED cohort was 33.5 mm compared with 39.2 mm in the lower BED group, which suggests that BED may in part be a surrogate for tumor size. Still, the improved survival in patients treated with SBRT to a BED~10~ ≥100 versus BED~10~ \<100 persisted after propensity-adjustments and generates the hypothesis that radiation treatment, particularly at highly ablative doses, may have the potential to significantly alter the disease course in treated patients. This analysis supports prior single center studies that generally explored SBRT for primary kidney cancer with highly ablative doses[@bib4], [@bib5], [@bib6] and ongoing prospective clinical trials.[@bib15]

For patients who are not ideal candidates for surgical resection, potential options include tumor ablation with cryotherapy or radiofrequency ablation, SBRT, or observation. SBRT may be an attractive treatment option for many patients for several reasons. First, SBRT is able to treat tumors larger than 4 cm or tumors located near the renal pelvis, criteria which are generally unsuitable for interventional radiology--guided tumor ablation.[@bib16]^,^[@bib17] In this analysis, nearly 40% of SBRT tumors were \>4 cm, compared with just 12% of ablated tumors. Second, SBRT is a noninvasive treatment with no associated anesthesia risk or prolonged recovery time. Third, SBRT is convenient for the patient, with treatment generally completed in 5 days or less or, in many cases, in a single day.

Limitations include the small number of patients treated with SBRT compared with other cohorts and the potential for confounding factors. Without information on cancer specific mortality or cause of death, and in a disease where overall outcomes are expected to be favorable,[@bib18] it is unclear whether the observed differences are related to differences in treatment or patient selection. Our findings of improved OS in patients treated with BED~10~ ≥100 compared with \<100 are surprising because the risk of distant metastases and cancer-specific death in patients with T1N0M0 kidney cancer is relatively low.[@bib19], [@bib20], [@bib21], [@bib22] Indeed, prior single institutional studies of kidney SBRT demonstrated very low rates of local failure.[@bib4], [@bib5], [@bib6] Even if higher BED~10~ leads to improved local control, it is unclear if this would drive a survival benefit in this population during this period of follow-up.

Other limitations include the potential for discrepancies between staging technique between treatment cohorts (ie, patients treated with SBRT are staged only clinically, compared with those undergoing surgery who are staged pathologically). In addition, this analysis grouped together patients treated with both total and partial nephrectomy, although these are distinct treatments with likely distinct outcomes. Furthermore, we excluded any patients who received systemic therapy as a component of initial treatment, which may erroneously exclude patients receiving planned adjuvant systemic therapy after surgery, tumor ablation, or SBRT. Additionally, patients with less than 2.67 months of follow-up were excluded in an attempt to reduce lead time bias. Although such exclusion criteria may limit capture of perioperative or treatment-related mortality, perioperative mortality after nephrectomy or partial nephrectomy is low.[@bib23] Finally, this study does not include cases treated in the past several years given the nature of national cancer database reporting and the lag between treatment and data collection and distribution.

Conclusions {#sec5}
===========

SBRT for early stage kidney cancer may be a promising noninvasive treatment option for nonsurgical patients. Despite the small number of patients treated with SBRT and potential for unmeasured confounding factors, a national registry study such as this may be the only current viable way to compare outcomes after SBRT in early stage kidney cancer given its extremely limited utilization at present. The efficacy and safety of this approach is being evaluated in ongoing prospective clinical trials.[@bib15]
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[^1]: *Abbreviations*: NOS = not otherwise specified; SBRT = stereotactic body radiation therapy.

[^2]: *Abbreviations*: BED = biological effective dose; NOS = not otherwise specified; SBRT = stereotactic body radiation therapy.

[^3]: *Abbreviations*: BED = biological effective dose; SBRT = stereotactic body radiation therapy.

[^4]: *Abbreviations:* BED = biological effective dose; OS = not otherwise specified; SBRT = stereotactic body radiation therapy.

[^5]: Models additionally adjusted for age at diagnosis, race, sex, year of diagnosis, Charlson-Deyo comorbidity score, tumor size, laterality, histology, grade, insurance plan, rurality, median income, education, academic hospital, distance traveled for treatment and propensity score.

[^6]: *Abbreviations*: BED = biological effective dose; CI = confidence interval; HR = hazard ratio; NOS = not otherwise specified; SBRT = stereotactic body radiation therapy.

[^7]: Models additionally adjusted for age at diagnosis, race, sex, year of diagnosis, Charlson-Deyo comorbidity score, tumor size, laterality, histology, grade, insurance plan, rurality, median income, education, academic hospital, distance traveled for treatment and propensity score.
